Compare Tango Therapeutics Inc. (TNGX) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Direxion Daily FTSE China Bull 3x Shares trades at $24.13 (market cap $600.54M). The key difference: Tango Therapeutics Inc. is far larger — about 6.2× Direxion Daily FTSE China Bull 3x Shares's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Direxion Daily FTSE China Bull 3x Shares for 26 Days on average.
| TNGX | YINN | |
|---|---|---|
Market Cap | $3.75B | $600.54M |
Volume | 9,619,106 | 729,546 |
Sector | Health | Leveraged / Inverse |
52-Week High | $32.90 | $52.69 |
52-Week Low | $7.50 | $21.45 |
Typical Hold Time | 0 Days | 26 Days |
Enterprise Value | $2.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
YINN trades at $25.06, up 0.36% with bearish technical signals from moving averages. The stock shows neutral momentum oscillators with RSI at 44.85. Recent news highlights China's economic policies affecting Asian markets, though YINN's specific financial metrics remain undisclosed in current data. The stock faces concentrated support/resistance around $25.
Outlook remains cautious with technical indicators suggesting bearish pressure. Investment opportunity depends on China's economic recovery and policy developments. Key risks include regulatory changes and market volatility. Analyst consensus and institutional positioning data are currently unavailable for assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
